Effect of Cabergoline on biochemical and anthropometric parameters of patient with Impaired Glucose metabolism (Impaired Fasting Glucose/Impaired Glucose Tolerance)

Phase 2

Recruiting

• Conditions: Prediabetes; Metabolic and Endocrine - Metabolic disorders

• Registration Number: ACTRN12613001121752
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-10-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Fasting Plasma Glucose (FPG): 100-110 mg/dL or/and 2 hour Plasma Glucose after Oral Glucose Tolerance Test (2hPG): 140-199 mg/dL.

Exclusion Criteria

1) severe hepatic failure (Child-Pugh scores of 10 or higher)
2) history of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders; increased risk of pleural effusion/pulmonary fibrosis
3) hypersensitivity to ergot derivatives
4) uncontrolled hypertension
5) Diabetes
6) Pregnant Women
7) Lactating Women
8) Major psychiatric disorders
9) Recieving Medication effect prolactin secretion
10) Bulimia or/and anorexia nervosa

Study & Design

• Study Type: Interventional
• Study Design: Not specified